Literature DB >> 15875085

EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients.

J Niemiec1, L Kolodziejski, S Dyczek.   

Abstract

In literature there are still opinion differences concerning the prognostic significance of epidermal growth factor receptor (EGFR) expression and proliferative potential in patients with non small cell lung cancer (NSCLC). This prompted us to study those parameters. The Ki-67 labeling index (Ki-67 LI), EGFR labeling index (EGFR LI), and mitotic index (MI) were analyzed in the group of 78 consecutive, surgically treated squamous cell lung cancer (SqCLC) patients. The expression of Ki-67 and EGFR protein was visualized on formalin fixed, paraffin embedded sections using immunohistochemistry (IHC). Mitotic index was assessed on formalin fixed, paraffin embedded sections, stained with hematoxylin and eosin using morphological criteria. Mean values of Ki-67 LI and MI were higher for G2+G3 tumors than for G1 tumors. EGFR LI was higher for G1+G2 than for G3 tumors, and for pT3 than for pT1+pT2 tumors. Patients having tumors with Ki-67 < or =28% or (EGFR LI < or =13% or EGFR LI >80%) survived significantly shorter than those having tumors with Ki-67 LI >28% or 13%< EGFR LI < or =80%. In multivariate analysis, 13%> or = EGFR LI <80% and Ki-67 LI < or =28% were independent negative prognostic parameters influencing survivals of SqCLC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875085

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung.

Authors:  Yan Xu; Biao Liu; Qun-Li Shi; Pei-Lin Huang; Xiao-Jun Zhou; Heng-Hui Ma; Zhen-Feng Lu; Yu Bo; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Int J Clin Exp Med       Date:  2014-08-15

4.  The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels.

Authors:  Ioannis Tsakiris; Gyorgyike Soos; Zoltan Nemes; Sandor Sz Kiss; Csilla Andras; Janos Szantó; Balazs Dezso
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-06       Impact factor: 4.553

5.  EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases.

Authors:  Ahmet Gokhan Gundogdu; Sevgen Onder; Pinar Firat; Riza Dogan
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

6.  Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.

Authors:  Svjetlana Radović; Mirsad Babić; Mirsad Dorić; Ajna Hukić; Suada Kuskunović; Ademir Hadzismajlović; Fadila Serdarević
Journal:  Bosn J Basic Med Sci       Date:  2007-08       Impact factor: 3.363

7.  Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.

Authors:  Dan-Ming Wei; Wen-Jie Chen; Rong-Mei Meng; Na Zhao; Xiang-Yu Zhang; Dan-Yu Liao; Gang Chen
Journal:  Respir Res       Date:  2018-08-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.